Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.86)
# 1,629
Out of 5,043 analysts
45
Total ratings
38.24%
Success rate
55.18%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $13.40 | +11.94% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.29 | +729.69% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $13.58 | +120.91% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.35 | +1,529.63% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.68 | +147.93% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $23.31 | +436.25% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $4.79 | +275.78% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.74 | +408.02% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.29 | - | 1 | Oct 1, 2021 | |
| PANW Palo Alto Networks | Maintains: Outperform | $75 → $79 | $220.29 | -64.06% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $63.50 | +144.09% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.12 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $9.45 | +164.55% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $6.13 | +29,263.78% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $36.48 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.88 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.94 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.59 | +41,682.73% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.91 | +47,020.42% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $8.70 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $12.98 | +1,171.19% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $99.98 | +125.05% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $8.10 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.60 | - | 2 | Jan 4, 2017 |
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $13.40
Upside: +11.94%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.29
Upside: +729.69%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $13.58
Upside: +120.91%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.35
Upside: +1,529.63%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.68
Upside: +147.93%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $23.31
Upside: +436.25%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $4.79
Upside: +275.78%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.74
Upside: +408.02%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.29
Upside: -
Palo Alto Networks
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $220.29
Upside: -64.06%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $63.50
Upside: +144.09%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $10.12
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $9.45
Upside: +164.55%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $6.13
Upside: +29,263.78%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $36.48
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.88
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.94
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.59
Upside: +41,682.73%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.91
Upside: +47,020.42%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $8.70
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $12.98
Upside: +1,171.19%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $99.98
Upside: +125.05%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $8.10
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $2.60
Upside: -